𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Results of a 2-Stage, Phase 3 Pivotal Trial, EDEMA3®: A Study of Subcutaneous DX-88 (Ecallantide), a Plasma Kallikrein Inhibitor, in Patients with Hereditary Angioedema (HAE)

✍ Scribed by LEVY, R; MCNEIL, D; LI, H; HSU, F; HORN, P; ROBERTS, J


Book ID
119279821
Publisher
Elsevier Science
Year
2008
Tongue
English
Weight
50 KB
Volume
121
Category
Article
ISSN
1097-6825

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES